» Articles » PMID: 28503515

Synthetic Versus Biological Mesh-Related Erosion After Laparoscopic Ventral Mesh Rectopexy: A Systematic Review

Overview
Journal Ann Coloproctol
Date 2017 May 16
PMID 28503515
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: This review reports the incidence of mesh-related erosion after ventral mesh rectopexy to determine whether any difference exists in the erosion rate between synthetic and biological mesh.

Methods: A systematic search of the MEDLINE and the Ovid databases was conducted to identify suitable articles published between 2004 and 2015. The search strategy capture terms were laparoscopic ventral mesh rectopexy, laparoscopic anterior rectopexy, robotic ventral rectopexy, and robotic anterior rectopexy.

Results: Eight studies (3,956 patients) were included in this review. Of those patients, 3,517 patients underwent laparoscopic ventral rectopexy (LVR) using synthetic mesh and 439 using biological mesh. Sixty-six erosions were observed with synthetic mesh (26 rectal, 32 vaginal, 8 recto-vaginal fistulae) and one (perineal erosion) with biological mesh. The synthetic and the biological mesh-related erosion rates were 1.87% and 0.22%, respectively. The time between rectopexy and diagnosis of mesh erosion ranged from 1.7 to 124 months. No mesh-related mortalities were reported.

Conclusion: The incidence of mesh-related erosion after LVR is low and is more common after the placement of synthetic mesh. The use of biological mesh for LVR seems to be a safer option; however, large, multicenter, randomized, control trials with long follow-ups are required if a definitive answer is to be obtained.

Citing Articles

Feasibility and safety of biologic OviTex mesh in ventral mesh rectopexy: a prospective pilot study.

Boom M, van der Schans E, Wijffels N, Verheijen P, Consten E Tech Coloproctol. 2025; 29(1):65.

PMID: 39948225 PMC: 11825524. DOI: 10.1007/s10151-024-03097-w.


Mesh-associated complications in minimally invasive ventral mesh rectopexy: a systematic review.

Hess G, Nocera F, Taha-Mehlitz S, Christen S, von Strauss Und Torney M, Steinemann D Surg Endosc. 2024; 38(12):7073-7082.

PMID: 39516323 PMC: 11614941. DOI: 10.1007/s00464-024-11369-7.


Ventral mesh rectopexy for recurrent rectal prolapse after Altemeier perineal proctosigmoidectomy: feasibility and outcomes.

Schabl L, Hull T, Erozkan K, Alipouriani A, Ban K, Steele S Langenbecks Arch Surg. 2024; 409(1):49.

PMID: 38305915 PMC: 10837248. DOI: 10.1007/s00423-024-03227-w.


The international variability of surgery for rectal prolapse.

Kelley J, Hagen E, Gurland B, Stevenson A, Ogilvie Jr J BMJ Surg Interv Health Technol. 2023; 5(1):e000198.

PMID: 38020494 PMC: 10649678. DOI: 10.1136/bmjsit-2023-000198.


Moving from Laparoscopic Synthetic Mesh to Robotic Biological Mesh for Ventral Rectopexy: Results from a Case Series.

Drissi F, Rogier-Mouzelas F, Fernandez Arias S, Podevin J, Meurette G J Clin Med. 2023; 12(17).

PMID: 37685818 PMC: 10488879. DOI: 10.3390/jcm12175751.


References
1.
Lezoche E, Paganini A, Fabiani B, Balla A, Vestri A, Pescatori L . Quality-of-life impairment after endoluminal locoregional resection and laparoscopic total mesorectal excision. Surg Endosc. 2013; 28(1):227-34. DOI: 10.1007/s00464-013-3166-2. View

2.
Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J . Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003; 73(9):712-6. DOI: 10.1046/j.1445-2197.2003.02748.x. View

3.
DAmbrosio G, Paganini A, Balla A, Quaresima S, Ursi P, Bruzzone P . Quality of life in non-early rectal cancer treated by neoadjuvant radio-chemotherapy and endoluminal loco-regional resection (ELRR) by transanal endoscopic microsurgery (TEM) versus laparoscopic total mesorectal excision. Surg Endosc. 2015; 30(2):504-511. DOI: 10.1007/s00464-015-4232-8. View

4.
DHoore A, Cadoni R, Penninckx F . Long-term outcome of laparoscopic ventral rectopexy for total rectal prolapse. Br J Surg. 2004; 91(11):1500-5. DOI: 10.1002/bjs.4779. View

5.
Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8(5):336-41. DOI: 10.1016/j.ijsu.2010.02.007. View